What it's for (Indications)
- Iron isomaltoside 1000 is an intravenous iron preparation primarily indicated for the treatment of iron deficiency when oral iron preparations are ineffective, contraindicated, or cannot be tolerated.
- This includes patients with various underlying conditions such as chronic kidney disease (CKD) who are on dialysis or pre-dialysis, patients with inflammatory bowel disease (IBD) experiencing iron deficiency anemia, and those with chemotherapy-induced anemia.
- It is also utilized in situations where a rapid iron repletion is clinically necessary, such as severe post-partum anemia, pre-operative anemia in patients awaiting surgery to minimize the need for blood transfusions, or in other scenarios demanding prompt iron correction.
- The diagnosis of absolute iron deficiency, characterized by low serum ferritin levels, reduced transferrin saturation, and often accompanied by microcytic hypochromic anemia, must be confirmed by appropriate laboratory tests prior to administration.
- Its high-dose single-infusion capability makes it particularly beneficial for patients requiring substantial iron supplementation, offering a convenient alternative to multi-dose oral regimens or multiple lower-dose intravenous infusions.
- The decision to administer iron isomaltoside 1000 should always be made by a healthcare professional experienced in the management of iron deficiency, considering the patient's overall clinical status and iron parameters.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Specific dosage guidelines were not provided in the available data. Clinical dosing should be determined by a healthcare professional based on patient iron deficiency severity and body weight. |
Safety & Warnings
Common Side Effects
- As with any intravenous iron preparation, iron isomaltoside 1000 carries a risk of adverse reactions, some of which can be serious.
- The most commonly reported side effects include transient taste perversion (metallic taste), nausea, vomiting, abdominal pain, and alterations in bowel habits such as diarrhea or constipation.
- Infusion-related reactions, including headache, dizziness, flushing, and localized pain or swelling at the injection site, are also frequently observed.
- A significant concern is the potential for hypersensitivity reactions, which can range from mild skin rashes, urticaria, or pruritus to severe and potentially life-threatening anaphylactic shock.
- Patients must be closely monitored during and for at least 30 minutes after infusion for any signs of hypersensitivity.
- Other reported adverse events include transient hypotension or hypertension, tachycardia, arthralgia, myalgia, back pain, and fever.
- Rarely, patients may experience phlebitis at the injection site or extravasation, which can lead to persistent skin discoloration.
- Delayed hypersensitivity reactions, manifesting as flu-like symptoms (e.
- g.
- , arthralgia, myalgia, fever), can occur several hours to several days post-infusion.
- Careful patient selection, pre-screening for a history of allergies, and immediate availability of resuscitation equipment and personnel are crucial to manage potential adverse events effectively.
Serious Warnings
- Black Box Warning: Iron isomaltoside 1000, like other intravenous iron preparations, carries a significant risk of serious hypersensitivity reactions, including life-threatening anaphylaxis and anaphylactic shock. These reactions can manifest rapidly and may occur even if previous administrations have been well-tolerated and without incident. Healthcare providers must ensure that full resuscitation equipment and personnel trained to evaluate and manage anaphylactic reactions are immediately available during and following administration. Patients should be closely monitored for signs and symptoms of hypersensitivity for at least 30 minutes after each infusion. Acute hypersensitivity reactions can include symptomatic hypotension, collapse, loss of consciousness, and cardiac arrest. Individuals with a history of allergies, asthma, eczema, or other allergic conditions are at increased risk and require particular caution and closer monitoring. Furthermore, rapid intravenous administration may lead to symptomatic hypotension, highlighting the critical importance of adhering to recommended infusion rates and pre-infusion assessment of patient hemodynamics to mitigate this risk.
- Caution is advised in patients with a history of allergic disorders such as asthma and eczema.
- It is suggested to avoid use in patients with compromised liver disease and hepatitis.
- For use during pregnancy and lactation, consult a healthcare professional.
How it Works (Mechanism of Action)
Iron isomaltoside 1000 is a highly stable, non-dextran intravenous iron complex designed for efficient iron delivery and controlled release. Structurally, it consists of a ferric hydroxide core surrounded by a synthetic isomaltoside oligosaccharide shell. Following intravenous administration, the large molecular weight and compact structure of the iron isomaltoside complex ensure that it remains intact in the bloodstream, minimizing the release of free iron. The complex is primarily taken up by the reticuloendothelial system (RES), particularly by macrophages in the liver, spleen, and bone marrow. Within these phagocytic cells, the iron is released from the isomaltoside complex in a controlled and gradual manner. The released ferric iron (Fe3+) is then either incorporated into intracellular iron stores, mainly as ferritin, or bound to transferrin in the plasma. Transferrin, the primary iron-transport protein, subsequently delivers the iron to erythroid progenitor cells in the bone marrow, where it is utilized for heme and hemoglobin synthesis. The isomaltoside carbohydrate ligand is designed to facilitate this controlled release, thereby reducing the risk of free iron-induced oxidative stress and hypersensitivity reactions commonly associated with less stable iron preparations. This controlled delivery mechanism allows for the administration of high doses of elemental iron in a single infusion, ensuring efficient iron utilization for erythropoiesis while maintaining patient safety.
Commercial Brands (Alternatives)
No other brands found for this formula.